+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Tract Infection Therapeutic Market by Therapeutic Type (Antibiotics, Antivirals, Cough Suppressants), Infection Type (Lower Respiratory Tract Infection, Upper Respiratory Tract Infection), Patient Type, Route Of Administration - Global Forecast 2025-2030- Product Image
Respiratory Tract Infection Therapeutic Market by Therapeutic Type (Antibiotics, Antivirals, Cough Suppressants), Infection Type (Lower Respiratory Tract Infection, Upper Respiratory Tract Infection), Patient Type, Route Of Administration - Global Forecast 2025-2030- Product Image
Sale

Respiratory Tract Infection Therapeutic Market by Therapeutic Type (Antibiotics, Antivirals, Cough Suppressants), Infection Type (Lower Respiratory Tract Infection, Upper Respiratory Tract Infection), Patient Type, Route Of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012375
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Respiratory Tract Infection Therapeutic Market is experiencing robust growth and strategic evolution driven by changing clinical demands, advancing technology, and increasingly complex global dynamics. Senior leaders navigating this space require deep insights into therapeutic innovations, shifting regulatory frameworks, and competitive benchmarks to make informed strategic decisions.

Market Snapshot: Respiratory Tract Infection Therapeutic Market

The Respiratory Tract Infection Therapeutic Market grew from USD 48.43 billion in 2024 to USD 51.85 billion in 2025. It is expected to continue growing at a CAGR of 7.23%, reaching USD 73.64 billion by 2030. This sustained expansion reflects the escalating demand for targeted therapeutics, innovation in delivery mechanisms, and intensified interest from both multinational pharmaceutical companies and specialized biotech players. Accelerated regulatory adaptations and increased focus on unmet clinical needs underline the market's continued momentum and relevance for decision-makers.

Scope & Segmentation: Deep-Dive Into Critical Market Segments

  • Therapeutic Type: Includes antibiotics (fluoroquinolones, macrolides, penicillins, tetracyclines), antivirals, cough suppressants, nasal decongestants, and non-steroidal anti-inflammatory drugs.
  • Infection Type: Captures lower and upper respiratory tract infection treatments, each shaping targeted delivery strategies and pharmacological innovation.
  • Patient Type: Covers adults, geriatrics, and pediatrics. Each segment demands tailored dosing protocols, safety monitoring, and patient-friendly formulations to address specific population needs.
  • Route of Administration: Encompasses inhalation (metered dose inhalers, nebulizers), oral (liquid suspensions, tablets), and parenteral routes, reflecting diverse approaches for acute and chronic care.
  • Geographic Coverage: Markets in the Americas (notably the United States by region and additional countries), Europe, Middle East & Africa (including the UK, Germany, France, Russia, and selected Middle Eastern and African nations), and Asia-Pacific (such as China, India, Japan, Australia, and Southeast Asian countries).
  • Key Industry Players: Abbott Laboratories, Alkem Laboratories, AstraZeneca, Boehringer Ingelheim, Cadila Healthcare, Cipla, F. Hoffmann-La Roche, GlaxoSmithKline, Glenmark, Hikma Pharmaceuticals, Intas, Lupin, Merck & Co., Mylan (Viatris), Novartis, Pfizer, Sanofi, Steris Healthcare, Teva.

Key Takeaways for Strategic Decision-Makers

  • Technological innovation in diagnostics is expediting pathogen detection, enabling rapid treatment adjustments and supporting better patient outcomes through precision management.
  • Integration of digital health solutions is fostering real-time monitoring, remote therapy adjustments, and improving adherence, particularly within complex or chronic infection settings.
  • Market segmentation by patient demographics and route of administration is driving the emergence of targeted, population-specific formulations to enhance safety and clinical effectiveness.
  • Regulatory environments are evolving to expedite approvals for advanced therapies, promoting collaboration across public and private entities for faster entry to market.
  • Antimicrobial stewardship is guiding both research priorities and product development, ensuring innovation aligns with long-term sustainability and resistance management.
  • Regional strategies are essential, as infrastructure, healthcare access, and market access programs vary widely across the Americas, EMEA, and Asia-Pacific, impacting product adoption and lifecycle planning.

Tariff Impact: Navigating U.S. Policy Changes

Recent tariff policy updates in the United States have introduced increased costs for select chemical precursors and active pharmaceutical ingredients essential to respiratory infection therapies. Manufacturers respond by diversifying suppliers, pursuing near-shoring strategies, and innovating procurement models to sustain supply chain reliability. These adjustments further reinforce the need for agility in supply management and adaptive commercialization strategies to ensure uninterrupted patient access and program continuity.

Methodology & Data Sources

This report utilizes a dual approach, combining comprehensive secondary research with targeted primary interviews. Peer-reviewed journals, regulatory filings, and clinical trial registries establish the macro landscape, while insights from industry leaders and clinical stakeholders validate real-world trends and innovation benchmarks. Cross-referencing public health statistics with proprietary surveys provides a robust multi-angle analysis, ensuring actionable guidance.

Why This Report Matters

  • Delivers differentiated, segment-specific perspectives tailored to the unique challenges of respiratory therapeutics, enabling leaders to shape high-impact portfolio and pipeline strategies.
  • Equips management teams with the tools to interpret evolving market conditions, streamline resource allocation, and accelerate time-to-market for novel formulations and diagnostic platforms.

Conclusion

This analysis distills the strategic imperatives and actionable insights required to effectively compete in the evolving Respiratory Tract Infection Therapeutic Market. Informed leadership and adaptive planning are key to sustaining growth and maximizing value creation in this dynamic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of long-acting inhaled monoclonal antibodies for RSV prophylaxis in high-risk adult populations
5.2. Integration of AI-driven diagnostic platforms for early detection of multi-viral respiratory infections in outpatient clinics
5.3. Expansion of broad-spectrum oral antiviral therapies targeting both influenza and emerging coronaviruses in clinical trials
5.4. Growing investor interest in inhalable RNA interference therapeutics for targeted suppression of respiratory virus replication
5.5. Strategic collaborations between biotech startups and established pharma for development of pegylated interferons in viral RTIs
5.6. Increasing use of smartphone-connected pulmonary function monitors for real-time tracking of infection progression at home
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Tract Infection Therapeutic Market, by Therapeutic Type
8.1. Introduction
8.2. Antibiotics
8.2.1. Fluoroquinolones
8.2.2. Macrolides
8.2.3. Penicillins
8.2.4. Tetracyclines
8.3. Antivirals
8.4. Cough Suppressants
8.5. Nasal Decongestants
8.6. Non-Steroidal Anti-Inflammatory Drugs
9. Respiratory Tract Infection Therapeutic Market, by Infection Type
9.1. Introduction
9.2. Lower Respiratory Tract Infection
9.3. Upper Respiratory Tract Infection
10. Respiratory Tract Infection Therapeutic Market, by Patient Type
10.1. Introduction
10.2. Adults
10.3. Geriatrics
10.4. Pediatrics
11. Respiratory Tract Infection Therapeutic Market, by Route Of Administration
11.1. Introduction
11.2. Inhalation
11.2.1. Metered Dose Inhalers
11.2.2. Nebulizers
11.3. Oral
11.3.1. Liquid Suspensions
11.3.2. Tablets
11.4. Parenteral
12. Americas Respiratory Tract Infection Therapeutic Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Respiratory Tract Infection Therapeutic Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Respiratory Tract Infection Therapeutic Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Abbott Laboratories
15.3.2. Alkem Laboratories Limited
15.3.3. AstraZeneca PLC
15.3.4. Boehringer Ingelheim GmbH
15.3.5. Cadila Healthcare Limited
15.3.6. Cipla Limited
15.3.7. F. Hoffmann-La Roche AG
15.3.8. GlaxoSmithKline plc
15.3.9. Glenmark Pharmaceuticals Limited
15.3.10. Hikma Pharmaceuticals PLC
15.3.11. Intas Pharmaceuticals Limited
15.3.12. Lupin Limited
15.3.13. Merck & Co., Inc.
15.3.14. Mylan Inc. by Viatris Inc.
15.3.15. Novartis International AG
15.3.16. Pfizer Inc.
15.3.17. Sanofi S.A.
15.3.18. Steris Healthcare Pvt. Ltd.
15.3.19. Teva Pharmaceutical Industries Ltd
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET: RESEARCHAI
FIGURE 24. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET: RESEARCHSTATISTICS
FIGURE 25. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET: RESEARCHCONTACTS
FIGURE 26. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 97. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 98. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 99. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 100. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 101. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 102. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 103. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 104. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 105. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 110. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 111. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 112. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 113. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 114. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 115. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 116. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 117. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 118. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 119. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 124. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 183. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 184. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 185. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 186. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 187. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 188. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 189. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 190. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 191. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 194. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 195. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 196. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 197. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 198. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 199. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 200. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 201. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 202. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 203. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 204. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 205. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 208. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 209. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 210. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 225. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 226. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 227. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 228. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 229. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 230. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 231. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 232. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 233. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 236. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 237. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 238. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 239. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 240. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 241. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 242. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 243. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 244. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 245. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 246. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 247. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 250. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 251. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 252. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2030 (U

Samples

Loading
LOADING...

Companies Mentioned

  • Abbott Laboratories
  • Alkem Laboratories Limited
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Cadila Healthcare Limited
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan Inc. by Viatris Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Steris Healthcare Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 51.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 73.64 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Anti-infectives Market by Product Type (Antibiotics, Antifungals, Antiparasitics), Indication (Bloodstream Infections, Gastrointestinal Infections, Respiratory Infections), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Anti-infectives Market by Product Type (Antibiotics, Antifungals, Antiparasitics), Indication (Bloodstream Infections, Gastrointestinal Infections, Respiratory Infections), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Upper Respiratory Tract Infection Treatment - Global Strategic Business Report - Product Image

Upper Respiratory Tract Infection Treatment - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Infectious Disease Therapeutics Market by Drug Class (Antibiotics, Antifungals, Antivirals), Route Of Administration (Inhalation, Intravenous, Oral), Indication, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Infectious Disease Therapeutics Market by Drug Class (Antibiotics, Antifungals, Antivirals), Route Of Administration (Inhalation, Intravenous, Oral), Indication, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Urinary Tract Infection Treatment Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Urinary Tract Infection Treatment Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 88 Pages
  • Global
From
Hospital Infection Therapeutics Market 2025-2029 - Product Image

Hospital Infection Therapeutics Market 2025-2029

  • Report
  • 231 Pages
  • Global
From

About the Respiratory Tract Infection Drug Market

The Respiratory Tract Infection Drug market is a subset of the larger Respiratory Drugs market. It includes drugs used to treat infections of the respiratory tract, such as bronchitis, pneumonia, and sinusitis. These drugs are typically antibiotics, antivirals, and anti-inflammatory medications. They are used to reduce symptoms, prevent complications, and reduce the spread of infection. The Respiratory Tract Infection Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, Sanofi, AstraZeneca, Novartis, and Johnson & Johnson. Other companies include AbbVie, Bristol-Myers Squibb, and Eli Lilly. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.